A Study of NX-1607 in Adults With Advanced Malignancies
← catalyst calendarNCT05107674 · readout in 11 d
Sponsored by Nurix Therapeutics, Inc. (industry) · NRIX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
345estimated
Sites
17
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-29 | actual | When the study began enrolling |
| Primary completion | 2026-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer, Epithelial
- Gastric Cancer
- GastroEsophageal Junction (GEJ) Cancer
- Head and Neck Squamous Cell Carcinoma
- Metastatic or Unresectable Melanoma
- Non-small Cell Lung Cancer (NSCLC)
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Malignant Pleural Mesothelioma (MPM)
- Triple Negative Breast Cancer (TNBC)
- Metastatic Urothelial Carcinoma
- Cervical Cancer
- Diffuse Large B Cell Lymphoma (DLBCL)
- Richter Transformation
- Microsatellite Stable Colorectal Carcinoma
Interventions
- Drug: NX-1607 — also filed as Cbl-b Inhibitor
- Drug: Paclitaxel
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs
measured 16 months
Incidence of immune-related AEs (irAEs), all deaths, and dose-limiting toxicities (DLTs)
measured Up to 2 Years
Objective Response Rate (ORR) per disease-specific response criteria as assessed by the Investigator
measured Up to 3 Years
Publications
- PMID 35362047 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NRIX's whole pipeline · Catalyst calendar · Every registered study · What changed